National and Kapodistrian University of Athens
Εφαρμογές του Gefitinib και συμπλοκών μικροεγκλεισμού Gefitinib κυκλοδεξτρινών: φυσικοχημικές ιδιότητες των φαρμάκων και μελέτη της δράσης τους σε κυτταρικές σειρές συμπαγών όγκων της παιδικής ηλικίας
Abstract
dc:descriptionIn the current work, we focused on the study of the effect of gefitinib in the presence or absence of cyclodextrins (CyDs), in neuroblastoma and glioblastoma cell lines, using biological assays. Also, we studied its inhibitory activity on EGFR tyrosine kinase domain of the receptor. In addition, we investigated the physicochemical and structural characteristics of gefitinib-cyclodextrin inclusion complexes, using complementary biophysical methods.We used neuroblastoma (SH-SY5Y, BE(2)M17) and glioblastoma (A172) cell lines , which were exposed to various concentrations of gefitinib, CyDs and gefitinib-cyclodextrin inclusion complexes (HP-β-CyD, DIMEB/TRIMEB). Cytotoxicity was assessed with alamar blue assay. EGFR expression was evaluated with immunohistochemistry and tyrosine phosphorylation of EGFR in the presence of gefitinib with ELISA assays.NMR spectra, allowed the elucidation of the structure of complexes (gefitinib/2-hydroxypropyl-β-CD, gefitinib/DIMEB, gefitinib/TRIMEB) in solution. Molecular modelling calculations and molecular dynamics simulations were made to predict the energy minimized structures of the complexes. In immunohistochemistry we observed that SH-SY5Y cells expressed higher levels of EGFR. ELISA assays in both cell lines showed gradual increase in EGFR tyrosine phosphorylation, as the concentration of gefitinib decreased, whilst EGFR levels were not altered. In alamar blue assay we observed that as the exposure time and as the concentration of gefitinib and gefitinib- β-CyDs complexes increased, cell viability decreased. The gefitinib/HP-β-CyD was the most effective combination in all tested concentrations. On the contrary, DIMEB/TRIMEB and HP-β-CyD did not have any effect on cell viability, except for the highest concentrations.With NMR we verified that the chlorofluorophenyl ring of gefitinib was included in the cavity of the CyDs and its solubility reached ~1.5 mM, 1.8 mM and 0.2 mM, in the presence of DIMEB, TRIMEB and HP-β-CyD, respectively.Gefitinib is insoluble to water and thus its reduced bioavailability is a very important issue in the treatment of cancer. In order to improve its low solubility, we obtained inclusion complexes of gefitinib with CyDs. We observed that gefitinib/DIMEB/TRIMEB and gefitinib/HP-β-CyD complexes were more effective in a time- and dose-dependent manner in all cell lines, when compared with the sole use of gefitinib. This could be attributed to the inclusion of the most hydrophobic part of gefitinib in the cavity of CyDs. In agreement with previous studies, we showed that the inhibition of EGFR could be an effective cytotoxic choice, especially in cancer cells lines which exhibit overexpression of EGFR or expression of mutated forms of EGFR.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Hatziagapiou, Kyriaki
- Χατζηαγαπίου, Κυριακή
Subjects
dc:subject × 16- Κυκλοδεξτρίνες
- Cyclodextrins
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Παιδιατρική, Νεογνολογία και Υγεία του παιδιού
- Ογκολογία
- Βασική Ιατρική
- Φαρμακολογία και Φαρμακευτική
- Μοριακή ιατρική
- Clinical Medicine
- Medical and Health Sciences
- Pediatrics, Perinatology and Child Health
- Oncology
- Basic Medicine
- Pharmacology and Pharmacy
- Molecular Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37728